Post-Systemic Chemotherapy Prognoses of Recurrent/Metastatic Soft Tissue Sarcoma Patients with Retroperitoneal/Intra-Abdominal Origin versus Those with Extremities/Trunk Origin
Kenji Nakano(National Center for Global Health and Medicine), Shunji Takahashi(Japanese Foundation For Cancer Research), Junichi Tomomatsu(The Cancer Institute Hospital), Keiko Hayakawa(Cancer Institute (WIA)), Ryosuke Oki(Tokushima University), Naoki Fukuda(The Cancer Institute Hospital), Makiko Ono(The Cancer Institute Hospital), Seiichi Matsumoto(Fukuda Denshi (Japan)), Taisuke Tanizawa(Japanese Foundation For Cancer Research), Shohei Udagawa(Japanese Foundation For Cancer Research), Akihiro Ohmoto(Japanese Foundation For Cancer Research), Mayu Yunokawa(Japanese Foundation For Cancer Research), Xiaofei Wang(Duke University), Naomi Hayashi(The Cancer Institute Hospital), Yusuke Minami(Hokkaido University), Keisuke Ae(The Cancer Institute Hospital), Tetsuya Urasaki(Japanese Foundation For Cancer Research), Hirotaka Suto(Japanese Foundation For Cancer Research), Yasuyoshi Sato(The Cancer Institute Hospital)
Cited by 0
Related Papers
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2021|412
Clear Cell Sarcoma of Soft Tissue
|The American Journal of Surgical Pathology|2008|283
Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A
|Proceedings of the National Academy of Sciences|2018|264